MINERALOCORTICOID RECEPTOR ANTAGONISM CLINICAL EVALUATION IN ATHEROSOCLEROSIS (MAGMA)

盐皮质激素受体拮抗剂在动脉粥样硬化 (MAGMA) 中的临床评估

• 批准号: 9404108
• 负责人: Sanjay Rajagopalan
• 金额: $ 62.85万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9404108
• 关键词: 3' Untranslated Regions; Affect; Aldosterone; Alpha Cell; Arterial Fatty Streak; Arteries; Atherosclerosis; Binding; Biology; Blood Pressure; Blood Vessels; Cardiovascular system; Cells; Clinical Trials; Complex; Computer Simulation; Data; Development; Disease; Disease Marker; Disease Pathway; Disease Progression; Double-Blind Method; Effectiveness; Event; Experimental Models; Flow Cytometry; Foundations; Future; Gene Expression; Generic Drugs; Genes; Glossary; Grant; Heart failure; Hour; Human; Inflammation; Inflammatory; Initiator Codon; Insulin Resistance; Laboratories; Lead; Ligands; Light; Link; Macrophage Activation; Magnetic Resonance Imaging; Measures; Metabolic; Methodology; Methods; MicroRNAs; Mineralocorticoid Receptor; Morbidity - disease rate; Myocardial Infarction; NR3C2 gene; Necrosis; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Open Reading Frames; Outcome; Outcome Measure; Pathway interactions; Patients; Pharmaceutical Preparations; Phenotype; Physiologic pulse; Placebo Control; Placebos; Play; Predisposition; Randomized; Randomized Controlled Clinical Trials; Randomized Controlled Trials; Receptor Activation; Regulation; Renin-Angiotensin System; Reporter; Resolution; Response Elements; Risk Marker; Role; Schedule; Small Interfering RNA; Stroke; TNF gene; Testing; Therapeutic Effect; Thoracic aorta; Transcript; base; cardiovascular risk factor; cell type; design; diabetic patient; effective therapy; eplerenone; hemodynamics; high risk; inhibitor/antagonist; insight; macrophage; monocyte; mortality; novel; novel marker; peripheral blood; predicting response; prevent; primary outcome; progression marker; promoter; prospective; protein expression; public health relevance; receptor; receptor expression; research clinical testing; response; response biomarker; secondary outcome; tumor

 DESCRIPTION (provided by applicant): We have previously demonstrated that the mineralocorticoid receptor (MR) plays an important role in inflammation in atherosclerosis. Studies from our laboratory suggest a role for monocyte MR activation in monocyte/macrophage inflammation. Further, we have demonstrated a key role for candidate microRNAs (miRNAs) in the regulation of MR (NR3C2) gene expression in monocytes and in the prediction of atherosclerosis. These findings suggest that miRNA expression predicts response to MR blockade in patients. We propose a randomized double blind clinical trial to assess the effect of MR antagonism on atherosclerosis in type II diabetes (DM). In Aim 1, we will test the effect of the MR antagonist Eplerenone (Epl) or placebo on progression of atherosclerosis using high resolution MRI. Key secondary outcomes will include central aortic blood pressure, pulse wave velocity, and measures of insulin resistance while tertiary measures include novel makers of heart failure predisposition. In Aim 2, we hypothesize that expression of monocyte miRNAs and macrophage phenotype may serve as markers of risk, disease progression, and response to MR antagonist. We propose investigating this in three, linked sub-aims. In Aim 2a, we will investigate the functional significance of single or multiple miRNAs involved in the regulation of MR expression using a promoter- reporter-3'UTR construct of the NR3C2 gene in cultured human macrophages. In Aim 2b, monocyte polarization and inflammatory genes will be compared at 6-weeks in Epl/placebo patients. In Aim 2c, at baseline we will measure the expression of miRNAs in monocytes predicted to regulate NR3C2. In addition we will measure NR3C2 transcript and/or protein expression in the same cells. Differential regulation of miRNAs after 6 weeks of treatment will be measured and used to understand disease progression and therapeutic effects of MR blockade. Using state of the art methods to quantify atherosclerosis with the latest advances in vascular biology, this proposal will offer an unprecedented opportunity to elucidate whether MR blockade is effective in atherosclerosis and further provide much needed insights on pathophysiologically relevant mechanisms and predictors of response. The insights from this study may lead to appropriately designed outcome trials.

 描述（由适用提供）：我们先前已经证明矿物皮质激素受体（MR）在动脉粥样硬化中炎症中起重要作用。我们实验室的研究表明，单核细胞MR激活在单核细胞/巨噬细胞炎症中的作用。此外，我们已经证明了候选microRNA（miRNA）在单核细胞中MR（NR3C2）基因表达的调节和动脉粥样硬化预测中的关键作用。这些发现表明，miRNA表达预测对患者MR阻滞的反应。我们提出了一项随机双盲临床试验，以评估MR拮抗作用对II型糖尿病（DM）中动脉粥样硬化的影响。在AIM 1中，我们将使用高分辨率MRI测试MR拮抗剂eplerenone（EPL）或安慰剂对动脉粥样硬化进展的影响。关键的次要结果将包括中央主动脉血压，脉搏波速度以及胰岛素抵抗的度量，而第三级措施包括心力衰竭易感性的新型制造者。在AIM 2中，我们假设单核细胞miRNA和巨噬细胞表型的表达可能是风险，疾病进展和对MR拮抗剂的反应的标志。我们建议在三个链接的子iams中对此进行调查。在AIM 2A中，我们将使用NR3C2基因在培养的人类巨噬细胞中使用NR3C2基因的启动子-3'UTR构建体调节MR表达的单个或多个miRNA的功能意义。在AIM 2B中，将在EPL/安慰剂患者的6周中比较单核细胞极化和炎症基因。在AIM 2C中，在基线时，我们将测量预测调节NR3C2的单核细胞中miRNA的表达。此外，我们将测量同一细胞中NR3C2转录本和/或蛋白质表达。治疗6周后，miRNA的差异调节将被测量，并用于了解MR封锁的疾病进展和治疗作用。该提案使用最新的血管生物学进展来量化动脉粥样硬化的状态，将提供前所未有的机会，以阐明MR Blockade在动脉粥样硬化中是否有效，并进一步提供有关病理生理学相关机制和反应的预测的很多病。这项研究的见解可能会导致适当设计的结果试验。